1999-08-23
Small
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Fine Chemical ManufacturingPharmaceuticals and Chemical Intermediates
Country / Region:
China
Company Type:
OtherListed company
Registered Capital:
22 million RMB
Company Capability: Process Technology Development
Liaoyuan Yinying Pharmaceutical Co., Ltd. is a national high-tech enterprise specializing in the research and development, manufacturing, and marketing of chemical pharmaceuticals, operating within the subsector of active pharmaceutical ingredient (API) and formulation manufacturing under the pharmaceutical manufacturing industry. The company’s core business encompasses R&D and large-scale production of chemical pharmaceutical formulations—including tablets, hard capsules, and granules—as well as APIs such as levocetirizine hydrochloride and ambroxol hydrochloride. Its flagship products include levocetirizine hydrochloride tablets (brand name: Dimin) and ambroxol oral solution. Multiple products have been included in the National Medical Insurance Drug List (2023 Edition) and the Essential Medicines Procurement Lists of numerous provincial governments. The company primarily serves hospitals at all levels and retail pharmacies, with market coverage concentrated across the three Northeastern provinces (Liaoning, Jilin, and Heilongjiang) and established regional market influence.
The company possesses independent R&D capabilities and hosts the “Jilin Province Anti-Allergy Drug Engineering Technology Research Center,” officially registered with the Jilin Provincial Department of Science and Technology. It holds five invention patents and three utility model patents; related technologies have been industrialized. In terms of qualifications, the company holds a “Pharmaceutical Production License” (No. Ji 20160197), with its certified scope covering all currently manufactured dosage forms and API varieties. Its production system consistently complies with China’s Good Manufacturing Practice (GMP) standards and has obtained ISO 9001:2015 Quality Management System certification. Its API manufacturing facility has completed the pre-assessment for the European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability (COS). All products are manufactured in accordance with the standards stipulated in the Chinese Pharmacopoeia (2020 Edition); the company currently holds over 20 domestic drug registration approvals.
Potential collaboration areas include contract manufacturing of pharmaceuticals, joint development, co-building of regional distribution channels, API supply, and technology transfer and commercialization. The company welcomes pragmatic cooperation with compliant pharmaceutical distributors, healthcare institutions, and R&D organizations possessing appropriate regulatory credentials and market resources.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































